You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Trimethoprim sulfamethoxazole decreased morbidity and mortality in HIV-1 infected patients with tuberculosis

https://doi.org/10.1136/ebm.5.2.55

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (1999) Lancet 353, 1469. Wiktor SZ, Sassan-Morokro M, Grant AD, et al.. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.. May 1;. :. –75.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In HIV-1 infected African patients being treated for tuberculosis, does the addition of trimethoprim sulfamethoxazole (co-trimoxazole) prophylaxis decrease morbidity and mortality?

    Design

    Randomised (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with median 10.5 month follow up.

    Setting

    4 outpatient tuberculosis treatment centres in Abidjan, Côte d'Ivoire.

    Patients

    771 patients (mean age 32 y, 60% men) who had sputum smears positive for tuberculosis, were HIV-1 positive, or dually reactive for HIV-1 and HIV-2, and met laboratory eligibility criteria (haemoglobin level ≥70 g/l, granulocyte count >1.1×109/l, platelet count >100×109/l, serum alanine aminotransferase level <2.5 times the upper limit of normal, and serum creatinine concentration <150 g/l). Exclusion criteria were …

    View Full Text

    Footnotes

    • Sources of funding: Centers for Disease Control and Prevention; Rockefeller Foundation; Roche African Research Foundation.

    • For correspondence: Dr S Wiktor, Projet RETRO-CI, 01 BP 1712, 01 Abidjan, Côte d'Ivoire. Fax +225 404 639 4268.

    • ↵* See glossary.